Collegium Pharmaceutical, Inc. announced it will present four posters showcasing real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting, held from April 3-6, 2025. This presentation underscores the company's commitment to advancing pain care. The data is expected to offer meaningful information for healthcare professionals.
One of the posters, titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids,” was selected as a top abstract. This distinction includes recognition and publication in AAPM’s Pain Medicine Journal, adding scientific credibility to Collegium's research. The presentations will occur on Friday, April 4.
Thomas Smith, M.D., Chief Medical Officer, stated that these collective data will provide real-world insights to support clinical decision-making. This initiative reinforces Collegium's position as a leader in responsible pain management and highlights important aspects of its medicines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.